Novartis' Lucentis could gain from German review of diabetes clinical guidelines
This article was originally published in Scrip
Executive Summary
IQWiG, Germany's Institute of Quality and Efficiency in Healthcare, is recommending some revision to the disease management programme for type 1 diabetes, which could be good news for Novartis' VEGF receptor antagonist Lucentis (ranibizumab), among other diabetic macular oedema treatments.